Literature DB >> 17404689

Combining immune cell and viral therapy for the treatment of cancer.

S H Thorne1, C H Contag.   

Abstract

A variety of viral-based and immune cell therapies have been proposed for use in the treatment of cancer. One possible approach to improve the effectiveness of these biological agents may be to combine them such that we can take advantage of natural immune cell-pathogen relationships. Here we discuss these potential approaches with particular emphasis on the use of immune cells as carrier vehicles to deliver viral therapies to the tumor.

Entities:  

Mesh：

Year:  2007        PMID： 17404689     DOI： 10.1007/s00018-007-6550-z

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN： 1420-682X            Impact factor:   9.261


  7 in total

1.  Synergistic interaction between oncolytic viruses augments tumor killing.

Authors:  Fabrice Le Boeuf; Jean-Simon Diallo; J Andrea McCart; Steve Thorne; Theresa Falls; Marianne Stanford; Femina Kanji; Rebecca Auer; Christopher W Brown; Brian D Lichty; Kelley Parato; Harold Atkins; David Kirn; John C Bell
Journal:  Mol Ther       Date:  2010-03-16       Impact factor: 11.454

2.  Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy.

Authors:  Stephen H Thorne; Wenchun Liang; Padma Sampath; Tobi Schmidt; Rachel Sikorski; Andreas Beilhack; Christopher H Contag
Journal:  Mol Ther       Date:  2010-07-06       Impact factor: 11.454

3.  Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.

Authors:  Padma Sampath; Jun Li; Weizhou Hou; Hannah Chen; David L Bartlett; Steve H Thorne
Journal:  Mol Ther       Date:  2012-12-11       Impact factor: 11.454

Review 4.  Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients.

Authors:  Sandeep S Patil; Ivaylo Gentschev; Ingo Nolte; Gregory Ogilvie; Aladar A Szalay
Journal:  J Transl Med       Date:  2012-01-04       Impact factor: 5.531

5.  Theranostic potential of oncolytic vaccinia virus.

Authors:  Juan J Rojas; Steve H Thorne
Journal:  Theranostics       Date:  2012-04-05       Impact factor: 11.556

6.  Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer.

Authors:  Emily K Mader; Greg Butler; Sean C Dowdy; Andrea Mariani; Keith L Knutson; Mark J Federspiel; Stephen J Russell; Evanthia Galanis; Allan B Dietz; Kah-Whye Peng
Journal:  J Transl Med       Date:  2013-01-24       Impact factor: 5.531

Review 7.  Designing and building oncolytic viruses.

Authors:  Justin Maroun; Miguel Muñoz-Alía; Arun Ammayappan; Autumn Schulze; Kah-Whye Peng; Stephen Russell
Journal:  Future Virol       Date:  2017-03-31       Impact factor: 1.831
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.